Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Comparative Clinical Pathology
Published in: Comparative Clinical Pathology 1/2018

01-01-2018 | Original Article

Comparison of SFRP2 promoter methylation in stool sample and cfDNA regarding patients with colorectal cancer

Authors: Mohsen Mohammadi, Seyed-Mojtaba Jafari, Mohammad-Ali Mohaghegh, Ali Ghasemi, Niloofar Momenzadeh

Published in: Comparative Clinical Pathology | Issue 1/2018

Login to get access

Abstract

Colorectal cancer (CRC) is one of the main causes of death in the world. Diagnosis in precancerous lesions stage is an important factor in reducing the mortality rate in CRC. Our study aimed at determining methylation status of secreted frizzled-related protein2 (SFRP2) gene in stool and serum samples of patients compared to healthy individuals. We collected serum and stool samples from 50 individuals including 25 patients with colorectal cancer and 25 healthy individuals. DNA was isolated from the serum and stool and treated by sodium bisulfite. It was then analyzed by methylation-specific polymerase chain reaction (MSP). Results showed that methylated SFRP2 occurs with significant different in patients with colorectal cancer compared to healthy individuals. Our result indicated that methylated SFRP2 occurs in 68% (17/25) and 48% (12/25) of stool DNA and cell-free DNA of patients with colorectal cancer, respectively. Methylated SFRP2 was detected in 8% (2/25) and 4% (1/25) of stool DNA and cfDNA of healthy individuals. Our result indicated that methylated SFRP2 occurred more frequently in stool DNA than cell-free DNA sample of patients with colorectal cancer. Methylated SFRP2 can be used as a potential noninvasive biomarker for screening high-risk individuals. In order to determine high sensitivity and specificity of this marker, more samples of Iranian individuals should be studied.
Literature
Babaei H et al (2016) DNA methylation analysis of secreted frizzled-related protein 2 gene for the early detection of colorectal cancer in fecal DNA. Niger Med J 57(4):242–245CrossRefPubMedPubMedCentral
Baylin SB et al (1986) DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Res 46(6):2917–2922PubMed
Caldwell GM et al (2004) The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 64(3):883–888CrossRefPubMed
Fodde R et al (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1(1):55–67CrossRefPubMed
Ghasemi A et al (2015) Methylation status of SOX17 and RUNX3 genes in acute leukemia. Iran J Blood Cancer 7(5):213–219
Ghasemi A, et al (2016) Methylation of the Wnt signaling antagonist, Wnt inhibitory factor 1 and Dickkopf-1 genes in acute myeloid leukemia at the time of diagnosis. Zahedan J Res Med Sci 18(1):1–1
Huang Z et al (2007) Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 52(9):2287–2291CrossRefPubMed
Kawano Y, Kypta R (2003) Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116(13):2627–2634CrossRefPubMed
Koga Y et al (2010) MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila) 3(11):1435–1442CrossRef
Kondo Y, Issa JPJ (2004) Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 23(1–2):29–39CrossRefPubMed
Malekzadeh R et al (2009) Epidemiology and molecular genetics of colorectal cancer in Iran: a review. Arch Iran Med 12(2):161–169PubMed
Marsit CJ et al (2006) Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. Int J Cancer 119(8):1761–1766CrossRefPubMed
Müller HM et al (2004) Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 363(9417):1283–1285CrossRefPubMed
Nojima M et al (2007) Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 26(32):4699–4713CrossRefPubMed
Pabby A et al (2005) Flexible sigmoidoscopy for colorectal cancer screening in the elderly. Dig Dis Sci 50(11):2147–2152CrossRefPubMed
Salehi R et al (2012) Methylation pattern of SFRP1 promoter in stool sample is a potential marker for early detection of colorectal cancer. Adv Biomed Res 1:87CrossRefPubMedPubMedCentral
Song K et al (2004) Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 126(5):1270–1279CrossRefPubMed
Suzuki H et al (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36(4):417–422CrossRefPubMed
Tang D et al (2008) Combination analysis of hypermethylated SFRP1 and SFRP2 gene in fecal as a novel epigenetic biomarker panel for colorectal cancer screening. J Nanjing Med Univ 22(2):96–101CrossRef
Wagner JL (1997) Cost-effectiveness of screening for common cancers. Cancer Metastasis Rev 16(3–4):281–294CrossRefPubMed
Whitney D et al (2004) Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn 6(4):386–395CrossRefPubMedPubMedCentral
Winawer S et al (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology 124(2):544–560CrossRefPubMed
Zhang W et al (2007) DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis Colon Rectum 50(10):1618–1627CrossRefPubMed
Zhang X et al (2015) Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas. World J Gastroenterol 21(9):2629–2637CrossRefPubMedPubMedCentral
Metadata
Title
Comparison of SFRP2 promoter methylation in stool sample and cfDNA regarding patients with colorectal cancer
Authors
Mohsen Mohammadi
Seyed-Mojtaba Jafari
Mohammad-Ali Mohaghegh
Ali Ghasemi
Niloofar Momenzadeh
Publication date
01-01-2018
Publisher
Springer London
Published in
Comparative Clinical Pathology / Issue 1/2018
Print ISSN: 1618-5641
Electronic ISSN: 1618-565X
DOI
https://doi.org/10.1007/s00580-017-2568-2

Other articles of this Issue 1/2018

Comparative Clinical Pathology 1/2018 Go to the issue

Brief Communication

Heat shock protein 70 of Trypanosoma evansi is phylogenitically closer to salivaria than stercoraria homologs

Original Article

Evaluating the performance of IFAT, RDT, and semi-nested PCR for detection of Leishmania infantum infection on sera samples in symptomatic dogs

Original Article

Preliminary use of Polygonum minus Linn. leaf extract on growth performance, feed utilization, and some hematological indices of Anabas testudineus (Bloch, 1792)

Original Article

The evaluation of the serum level of IL-10 in OLP patients

Brief Communication

Relationship between hyperglycemic states and glucose-6-phosphate dehydrogenase activity among patients with type 2 diabetes in Kano, Nigeria

Original Article

Hemato-immunological and plasma biochemical responses of silvery-black porgy (Sparidentex hasta) fed protein and essential amino acid deficient diets